Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
Karine Briot, Erik A. Imel(Indiana University – Purdue University Indianapolis), Robin Lachmann(University College London), Hae II Cheong(Seoul National University Children's Hospital), Annabel Nixon, Rachel Crowley(St. Vincent's University Hospital), Han‐Wook Yoo(CHA University Bundang Medical Center), Anthony A. Portale(University of California, San Francisco), Farzana Perwad(University of California, San Francisco), Mark Nixon, Thomas J. Weber(Duke Medical Center), Yasuhiro Takeuchi(University College London), Takuo Kubota(Osaka University Hospital), Martine Cohen‐Solal(Université Paris Cité), Maria Luisa Brandi, Wei Sun(Kirin (United States)), Nobuaki Ito(University of Tokyo Hospital), Richard Keen(Royal National Orthopaedic Hospital), Steven Ing(The Ohio State University Wexner Medical Center), Yasuo Imanishi(Osaka City University), Richard Eastell(University of Sheffield), M K Javaid(Southampton General Hospital), Karl Insogna(Children's Hospital at Westmead), Pisit Pitukcheewanont(Children's Hospital of Los Angeles), Peter Kamenický(Université Paris-Sud), Hiroyuki Tanaka(Okayama Saiseikai General Hospital), Stuart H. Ralston(University of Aberdeen), Suzanne M. Jan de Beur(Johns Hopkins University), Angela Williams(Kyowa Kirin International (United Kingdom)), Thomas O. Carpenter(Harvard University)
Cited by 72
Related Papers
Clinician’s Guide to Prevention and Treatment of Osteoporosis
|Osteoporosis International|2014|4.1k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k